| Oct 1 |
CTSO: CytoSorbents Announces Submission of DrugSorb-ATR Application to the FDA
|
| Oct 1 |
CytoSorbents spikes on FDA submission for DrugSorb-ATR
|
| Oct 1 |
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
|
| Aug 16 |
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Aug 14 |
Cytosorbents Corporation (CTSO) Q2 2024 Earnings Call Transcript
|
| Aug 13 |
CytoSorbents: Q2 Earnings Snapshot
|
| Aug 13 |
Cytosorbents GAAP EPS of -$0.08 beats by $0.02, revenue of $9.9M beats by $0.22M
|
| Aug 13 |
CytoSorbents appoints Peter J. Mariani as CFO
|
| Aug 13 |
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
|
| Aug 13 |
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
|
